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Abstract
Background: With more than 200,000 problem drug users is contact with structured treatment
services in England the public health imperative behind drug treatment is great. Problem drug use
for many is a chronic and relapsing condition, where "cure" is often neither a reasonable or
appropriate expectation and it can further be argued that in these circumstances problem drug use
is no different from any number of chronic and enduring health conditions that are managed in the
health care system and therefore should be conceptualised as such.
Discussion: A public health approach to drug treatment emphasises the need for drug users in or
accessing treatment, to reduce their harmful drug use, reduce drug use related risks such as sepsis
and overdose and stay alive for longer. However a public health perspective in relation to problem
drug use isn't always either apparent or readily understood and to that end there is still a significant
need to continue the arguments and debate that treatment and interventions for problem and
dependent drug users need to extend beyond an individualistic approach. For the purposes of
discussion in this article public and population health will be used interchangeably.
Summary: A recognition and acceptance that a public and population health approach to the
management of problem drug users is sound public health policy also then requires a long term
commitment in terms of staffing and resources where service delivery mirrors that of chronic
condition management.
Background
The history to substance misuse treatment and interven-
tions has cycled through a variety of ideologically driven
approaches and perspectives covering medicalisation,
treatment, decriminalisation, the overt use of the criminal
justice as quasi treatment as well as more accepting posi-
tions such as harm minimisation and harm reduction.
The purpose of this article is to continue the debate which
makes a case for a public and population health impera-
tive behind substance misuse treatment, highlighting the
chronic and enduring nature of substance misuse for
many along with the increase in morbidity and mortality
amongst drug users relative to their non drug user con-
temporaries, as well as the evidence base which underpins
effective treatment modalities.
Discussion
A Public Health Perspective
Figures from the National Treatment Agency for Sub-
stance Misuse (NTA) report that 207,580 individuals,
aged 18 and over, were recorded as being in contact with
structured drug treatment services in England for the
counting period 2008/09, this included General Practi-
tioners (GPs) providing structured treatments, that would
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typically, but not exclusively, be prescribing modalities;
this is a rise on the 2007/8 figures of 202,666 individuals
recorded as being in contact with structured drug treat-
ment services in England during 2007/8 which in turn is
an increase on the 2006/7 numbers of 195,464 of individ-
uals recorded as being in contact with specialist drug treat-
ment services and a further increase from the 2005/6 data
of 177,055 [1]. It is true that processes within the NTA and
the National Drug Treatment Monitoring System
(NDTMS) have changed over this time period which has
meant that some of the specifics of the data set and its def-
initions have altered, for example the inclusion criteria
changing from specialist services to structured treatment
services as well as more robust data collecting systems;
these changes could in themselves generate discussion
and debate around methods, methodology, data verifica-
tion and veracity. However that said these figures demon-
strate that problem drug use is not an insignificant issue
and moreover that since these figures represent only those
in contact with structured drug treatment services the
overall prevalence of problem drug users can be expected
to be substantially higher; on the basis of these statistics
alone it is clear that the population health impact of prob-
lem drug use cannot be doubted.
So what exactly is a public health perspective in relation to
problem drug use? The primary focus is one of reducing
harm amongst identified populations, and arguably the
best way of achieving this is by minimising risk. Harm
reduction can broadly be argued to be a range of policies,
programmes and interventions aimed at reducing the
harm caused by problem drug use [2,3] A more precise
definition from The International Harm Reduction Asso-
ciation is, "to reduce the health, social and economic
harms associated with the use of psychoactive substances"
[4]. Developing out of the rise of the Human Immunode-
ficiency Virus (HIV) in 1980s, harm reduction became a
significant public health force putting the population
health impact and consequences of problem drug use on
the political agenda [5,6]
Problematic Drug Use
A problem drug user can be defined as someone who
experiences a range of unwanted and negative conse-
quences as a result of their drug use [7] namely social, psy-
chological, physical or legal problems related to regular or
excessive consumption, intoxication and/or dependence.
The NTA describe problematic drug use as being a chronic
and relapsing condition [8] often taking several attempts
to achieve stability or abstinence, The World Health
Organisation (WHO) concur that problem drug use is
best regarded as a chronic behavioural disorder, where
controlling or stopping the problem drug use frequently
takes many attempts, and moreover that relapse is com-
mon [9] This is echoed further in that problem drug use,
for many, results in a repeated cycle of treatment, relapse
and recovery that might last for decades [10]
Chronic & Relapsing
The Royal Pharmaceutical Society in the UK have long
argued that treatment for problem drug use is likely to be
punctuated by times of crisis or relapse [11] and rather
than seeing these as a failure of the patient or programme,
recognising that problem drug use is frequently a chronic
and relapsing condition is a far more useful way of
explaining events. Often characterised as a career that typ-
ically lasts upwards of 10 years, problem drug use is
marked by oscillations between relapse and recovery [12]
These two concepts of relapse and recovery are both piv-
otal to an understanding and application of substance
misuse treatment [13,14] Covering several domains of
behaviour, relapse prevention aims to deal with obstruc-
tive and negative beliefs which lead to repeat behaviours.
The domains covered include; negative emotions, nega-
tive physical states, urges & cravings and dealing with
inter-personal conflicts. Effective relapse prevention strat-
egies can be particularly good at addressing relatively and
somewhat disruptively short treatment episodes, they also
provide an opportunity to better understand why relapse
occurs and what preventative measures can be put in
place, thus enabling clients to move forward.
The use of Recovery Management Checkups (RMCs) were
explored and found to be invaluable in enabling those
who have relapsed to be able to re-access treatment the net
result being that those utilising the RMCs re-entered treat-
ment sooner after dropping out, were in receipt of more
treatment and the time between relapse and treatment re-
entry was shortened significantly [15]. A conclusion
reached by some however is that for the majority of
chronic problem drug users the long term outcomes are
not favourable and that growing out of their substance
misuse simply does not apply [16]
The Royal College of General Practitioners in the UK also
regard substance misuse as being a chronic and relapsing
condition [17] and as such they make the important dis-
tinction that substance misuse should, conceptually at
least, be no different to any number of chronic conditions
managed in Primary Care. Chronic health conditions,
across the spectrum of physical and mental health are
often united by the single feature that cure is not an avail-
able option [18,19] however effective management of the
condition is achievable; ameliorating symptoms as neces-
sary and enabling patients and service users to recognise
what might trigger episodes of relapse is paramount to an
understanding of problem drug use, in much the same
way as other chronic conditions such as diabetes, heart
disease, multiple sclerosis, Parkinson's disease and endur-
ing mental illnesses are understoodSubstance Abuse Treatment, Prevention, and Policy 2009, 4:21 http://www.substanceabusepolicy.com/content/4/1/21
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Long term conditions are further characterised by poor
compliance and limited adherence to treatment plans and
advice, [20-24] Moreover in almost all the literature
reviewed there was an acknowledgement that the reasons
precipitating non-compliance were complex and varied
and not necessarily linked to lack of knowledge or the
ability to understand; concordance with treatment
regimes and advice requires both the client and the health
care professional to have the same perspectives and nego-
tiated goals.
The concept of compliance has been explored further [25]
and the observation made that for many clinicians their
definition of compliance is the extent to which the patient
or client takes the medication as it is prescribed, whilst
well defined this definition is also very restrictive and con-
cordance is probably a more useful term and is suggestive
of the need for clinicians to form a more effective thera-
peutic alliance with service users to facilitate them in
adhering to treatment plans rather than blaming them
when they don't [26-28] In the literature reviewed they all
make the fundamental point that compliance is best
achieved through a working relationship which is based
upon a shared understanding of the issues, how these
issues can best be addressed and placing the non compli-
ance within a context of understanding why people
default from optimal treatment rather than coming from
a moral perspective which is that they have in some way
failed. Compliance is frequently value laden where com-
pliance with advice is considered good and non-compli-
ance is seen as bad, this fundamental difference in moral
understanding seems to do little for developing an effec-
tive therapeutic alliance. A starting point which emanates
from professionally ingrained attitudes and beliefs seems
always to be fraught with dissonance.
Lack of compliance or dis-engagement from treatment has
little to do with the specifics of being a drug user, moreo-
ver this is better explained by the complexities of living
with a chronic (and relapsing) condition and how indi-
viduals make choices and endeavour to exercise some
control in situations and circumstances where this bal-
ance is otherwise skewed. Out with of the realms of addic-
tion probably the very best example of non compliance
affecting the general population is that of non completion
of courses of antibiotics [29,30] with an interesting
related observation being made that non-compliance or
non-adherence with prescribed treatment might be more
easily explained by study outcomes which identify that
patients cease to take the medication because they feel
better or because the prescribing regime was too onerous
or complicated to fit in with a normalised life style [31].
The parallels with opiate replacement prescribing are evi-
dent; being committed to a treatment modality might also
require frequent attendance at a community pharmacy or
treatment service in order to receive the prescribed treat-
ment and in turn this requires motivation to attend in the
belief that the outcome will be beneficial. The issue of
being sufficiently motivated to engage in substance mis-
use treatments is well documented [32-34] and most
notably by Sellman [35] where there is an overt reference
made to the dilemmas and limitations associated with
being required to be "sufficiently motivated" so as to
engage in treatment. The requirement to demonstrate
motivation seems also to stem from a moral perspective
that access to health care and services is frequently a reflec-
tion of being deserving or undeserving and that "tests" of
commitment will in someway sift out those who are not
serious, committed or motivated to change. One concern
however is that having to demonstrate motivation in
order to access treatment brings substance misuse treat-
ment back to the individualistic level and does little to
reduce the public and population health risks associated
with drug use, and injecting drug use in particular.
Problem Drug Use Treatments
Problem drug use treatment can typically be defined as
interventions that directly address or ameliorate the nega-
tive effects of problematic drug use and cover a broad
spectrum, from pharmacological interventions such as
substitute prescribing and detoxification, through to psy-
cho-social approaches including models of counselling
and behaviour modification namely Cognitive Behav-
ioural Therapy, Transtheoretical Model (cycle of change)
& Motivational Interviewing as well as specific harm
reduction interventions; needle exchange, Hepatitis
screening and vaccination programmes. As important as
the treatment and care is which directly addresses the
problem drug use, focusing exclusively on these treatment
interventions results in other drug use related issues such
as sexual health, pregnancy, mental and psychological
health falling outside the remit; the population's health
benefits most from being addressed and managed from an
inclusive i.e. public health and harm reductionist
approach.
Evidence supporting the benefits and gains that are
achieved through availability of treatment, even if absti-
nence is not achieved, is demonstrated through the litera-
ture and that being punishing or excluding does nothing
to reduce substance use, moreover it only creates situa-
tions where the level of harm and risk are escalated [36]
The benefits of unhindered and probably more controver-
sial unconditional access to treatment and health care for
problem drug users cannot be doubted. Patients retained
in methadone treatment within primary care improved on
a range of harm reduction measures including HIV risk-
taking behaviour as well as in their physical and psycho-
logical health [37] with others concluding that treatment
duration was associated with positive improvements in
primary drug use and that being in treatment was associ-Substance Abuse Treatment, Prevention, and Policy 2009, 4:21 http://www.substanceabusepolicy.com/content/4/1/21
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ated with a reduction of non fatal overdose that was
directly related to a reduction in high risk practices, dem-
onstrating that treatment can change behaviour [38,39]
Treatment also substantially increases the likelihood of
abstinence from illicit drugs, but even where abstinence is
not achieved there can still be substantial reductions in
frequency of use of heroin, non-prescribed methadone,
benzodiazepines, and crack cocaine; associated Injecting
and shared use of injecting equipment are also reduced
[40,41] further supporting the argument that the health of
populations can improve significantly when associated
drug use harms are reduced.
Substitute Prescribing
Substitute prescribing, as a harm reduction strategy, is
supported by the wealth of evidence that appropriately
and safely prescribed higher doses of long acting opioids
such as methadone are more effective in both reducing
illicit opiates use, and in retaining problem drug users in
treatment services for longer. Predictors of retention in
drug treatment have demonstrated over time to be inextri-
cably linked to therapeutic doses of methadone that are
higher than 60 mg per day, [42-47]
Allied to the retention in treatment is the reduction in
illicit opiate use, and with it a reduction in the attendant
risks of overdose, sepsis and exposure to communicable
disease, again there is significant evidence, over almost 2
decades that higher methadone doses assist drug users in
using less illicit opiates [48-53] Adopting a harm reduc-
tion philosophy towards drug treatment prescribing,
where illicit or non prescribed psychoactive drug use in
addition to prescribed treatments is acknowledged as
being likely to happen, rather than pursuing an enforced
abstinence as the eligibility criteria is further demon-
strated to retain clients in treatment, whilst at the same
time reducing their additional drug use [54-57]
Preventing the transmission of Communicable Disease
The benefits to the health of populations of preventing
the transmission of communicable diseases, particularly
blood borne virus, is well documented and in particular
the introduction of harm reduction interventions during
1980's is argued to account for the low prevalence of HIV
amongst injecting drug users in England seen during
1990's where the incidence of HIV prevalence amongst
injecting drug users declined from 5.9% in 1990 to 0.6%
in 1996 [58]. However, in contrast to the figures in Eng-
land there were exceptionally high rates of HIV infection
amongst Injecting Drug Users in Scotland, particularly
Edinburgh [59-62] with prevalence rates of 50% or more
[63,64] the lack of and in some case prohibition of needle
and syringe exchange programmes was not insignificant
in resulting in these numbers.
The expansion of needle exchange programmes have been
seen to be the single most effective harm reduction inter-
vention in keeping the transmission levels of HIV
amongst injecting drug users in the England at their con-
sistently low levels [65] Whilst not an invitation for com-
placency it does add weight to the continued argument
that as an intervention in reducing transmission of HIV
amongst injecting drug users needle exchange does work,
regardless of the arguments about the legality of heroin
use and does offer a differential perspective, one of keep-
ing the health benefits of treatment separate from those of
the Criminal Justice System.
Hepatitis C prevalence amongst Injecting Drug Users is
extremely high [66-70] Documented prevalence of Hepa-
titis C amongst injecting drug users being between 50-
90% and sharing injecting equipment and paraphernalia
is identified as the behaviour more likely to result in trans-
mission than any other risk taking behaviour [71-75]
Unlike with Hepatitis C there is however a recognised
method of preventing the spread of Hepatitis A & B
through effective and safe vaccination [76-79] The ease
with which transmission of these two viruses can occur
adds weight to the argument that a population health
approach is both essential and morally defensible, not
least of all the rapid transmission of Hepatitis A in close
social and domestic circumstances and the ease with
which Hepatitis B is transmitted both sexually and in
utero [80,81]
The UK's current Hepatitis B vaccination strategy has been
based upon the selective targeting of high risk groups [82-
84] and despite a rising prevalence amongst injecting drug
users and in particular those within prisons this continues
to be pursued [85,86] and whilst it is the case that the UK
does not experience the high endemicity and chronic car-
rier numbers present elsewhere [87-89] there is a wealth
of evidence that the recommendations made by the WHO
in 1992, namely that Hepatitis B should be incorporated
into national vaccination programme globally, was not
without foundation since vaccination works and is feasi-
ble to introduce [90,91] Moreover it also goes some way
to address the low risk perception and knowledge which
exists, particularly amongst young adults and most worry-
ingly amongst injecting drug users where there was often
a dissonance between their perception or belief of their
hepatitis status and laboratory virology [92-96].
It continues to be a source of debate that there is a dis-
torted logic which prevails where sections of the popula-
tion are offered effective protection via vaccination only
once they are exposed to the risks of Hepatitis B and there
then is a significant amount of effort required to redeem
the situation and encourage uptake of vaccination.Substance Abuse Treatment, Prevention, and Policy 2009, 4:21 http://www.substanceabusepolicy.com/content/4/1/21
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Reducing Drug Related Deaths
Morbidity and mortality frequently go hand in hand for
problem drug users, particularly injecting drug users [97]
Significant evidence exists that drug users are at a greater
risk of premature death than their non drug using contem-
poraries [98-101] with some estimates putting the differ-
ential 13-17 times greater than non drug users [102,103]
In terms of reducing drug related deaths, substitute pre-
scribing and in particular methadone maintenance is
demonstrated to be a protective factor against premature
death. In short, longer term opiate replacement therapy
keeps problem drug users in treatment for longer and
keeps those who are in treatment alive. Most importantly
however is the evidence that early or involuntary cessation
of methadone treatment, particularly due to a breach of
the treatment service rules, results in higher mortality
rates compared with those retained in treatment [104-
106]
The benefits of treatment, in reducing non-fatal overdose,
were also evident from the Australian Treatment Outcome
Study (ATOS) [107] with non fatal overdose rates over 12
months falling from 24% to 12%, methadone mainte-
nance treatment demonstrated a significant reduction in
overdose, from 22% to 4%. This reduction in overdose
was related to a reduction in the frequency of drug use and
lower rates of injecting. Unsurprisingly, as the discussion
has already demonstrated, more treatment episodes sug-
gestive of interrupted treatment and episodes that are
multiple but reduced in overall length and typically punc-
tuated by untimely disruption eg imprisonment, results in
an increased risk of overdose. Sustained and seamless
drug treatment has significant benefits in reducing prema-
ture deaths amongst problem drug users.
Summary
The primary focus of a public health approach to sub-
stance misuse is that of reducing harm amongst identified
populations
Substance misuse for many is deemed to be a chronic con-
dition often further characterised by poor compliance and
limited adherence to treatment plans and advice
Morbidity and mortality are high with premature deaths a
significant cause for concern
The evidence base in support of substitute prescribing
reports consistently that doses in excess of 60 mg per day
have better efficacy than lower (sub optimal doses)
Conclusion
The Public Health imperative behind substance misuse
treatments is best demonstrated when the rationale for
drug treatment accepts that for many who receive treat-
ment it is a chronic and frequently relapsing condition.
The purpose behind treatment needs to move away from
an individualistic approach to one which recognises drug
users exist in many and varied relationships and as part of
several communities, thus the health of populations
becomes a pivotal part of the treatment rationale. A public
health imperative for the delivery of drug treatments can
be seen to be effective in minimising the harm associated
with drug use, both for the individual and the communi-
ties they reside within. The use of needle exchanges in
reducing some blood borne virus transmission is clearly
demonstrated, clients retained in treatment for longer
have more favourable treatment outcomes, both drug use
and risk taking are reduced when prescribing policies for
opiate replacement are not contingent upon abstinence of
other substances and where appropriately prescribed
doses of methadone are in excess of 60 mg per day.
The reduction in drug related deaths, as a result of the
reduced frequency of accidental overdoses, and the wider
population health gains when treatment and interven-
tions are flexibly delivered is further evidence that the
health of populations can be improved with public health
based strategies for substance misuse. Whilst concordance
with treatment can at times be inconsistent, evidence
from the literature demonstrates that this is not the exclu-
sive preserve of problem drug users; it is however the very
nature of an enduring condition which means compliance
with treatment is often sub-optimal.
People change their behaviour in stages; few people make
radical life changing moves that take them from one
extreme to the other in a short period of time. This incre-
mental approach to behaviour change is both more sus-
tainable and manageable and more importantly views
relapse as part of the stages rather than being a value laden
judgement on the individual who is deemed to have
"failed". Limiting the cascade effect of drug related harm
within populations needs to be the philosophy adopted
and engaging in punitive battles with individuals serves
no useful purpose; moreover it actually serves only to use
individuals as scapegoats when the health of populations
is the responsibility of many and not the fault of the few.
To cure problem drug users is frequently not a reasonable
approach to take, and an over emphasis on moving peo-
ple on, through and out of treatment frequently results in
the revolving door phenomena; these are however both
politically challenging and contentious issues. Substitute
prescribing in particular can have a long term impact
upon service provision and capacity. When there is a real
understanding and acceptance that some in receipt of sub-
stitute prescribing do best when this is long term and at a
maintenance dose, what invariably follows has to be an
acceptance that substitute prescribing for some mightSubstance Abuse Treatment, Prevention, and Policy 2009, 4:21 http://www.substanceabusepolicy.com/content/4/1/21
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cover 5, 7, 10 or more years and this needs not only to be
accepted as being clinically appropriate but also likely to
occur and thus resourced appropriately. Only when indi-
viduals who use drugs in a problematic manner are
viewed as being part of a wider society and members of
dynamic social groups with families, friends and
acquaintances do the public health implications and ram-
ifications become obvious.
In the light of the evidence it is clear that problem drug
use is frequently a chronic and relapsing condition,
requiring ongoing management over a number of years or
decades, where the consequences go beyond the individ-
ual and is a condition that can and does result in prema-
ture and avoidable deaths. There is a pressing need that
public health principles should in fact be the foundation
of all drug treatment interventions, and that investment in
drug treatment is sound public health policy.
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